

Xspray Pharma - A year with pivotal potential ahead

Redeye ups its fair value range for Xspray in anticipation of a transformative year ahead. We have reassessed our forecast on the back of recent development for XS004/XS003 and the inclusion of XS008 into our valuation model. 2023 could prove to be an inflection point for the company, which is yet to be reflected in the share price.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

[Xspray Pharma - A year with pivotal potential ahead](#)